I think it is possible after Angelman but more importantly a favourable outcome in the post-phase 2 meeting with the FDA for Phelan McDermid syndrome which is slated for this quarter.
- Agreeance on what the protocol will be for the Phase 3 study (which would be similar for other indications)
- A modification/simplification for the protocol for the subsequent Phase 2 studies in other indications
- Subsequent to the meeting - the additional Phase 2 indications will be announced and will move as soon as possible
This gives a clear roadmap for commercialising NNZ-2591.
Acadia, page-782
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 582 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 16.36pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable